All-trans-retinoic acid (ATRA) is a vitamin A derivative that is important in neuronal patterning, survival, and neurite outgrowth. Neuroprotective effects of ATRA in ischemia have been demonstrated but its effects on glial swelling are not known. We investigated the relatively acute effects of ATRA on cell swelling in ischemic injury and on key features hypothesized to contribute to cell swelling including increased reactive oxygen species/ reactive nitrogen species (ROS/RNS), depolarization of the inner mitochondrial membrane potential (ΔΨ m ), and increased intracellular calcium ([Ca 2+ ] i ). C6 glial cultures were subjected to 5 hr oxygen-glucose deprivation (OGD). ATRA was added to separate groups after the end of OGD. OGD increased cell volume by 43%, determined at 90 min after the end of OGD, but this increase was significantly attenuated by ATRA. OGD induced an increase in ROS/RNS production in the whole cell and mitochondria, as assessed by the fluorescent dyes CM-H 2 DCFDA and MitoTracker CM-H 2 -XROS at the end of OGD. The increase in mitochondrial ROS, but not cellular ROS, was significantly attenuated by ATRA. OGD also induced a 67% decline in mitochondrial ΔΨ m but this decline was significantly attenuated by ATRA. OGD-induced increase in [Ca 2+ ] i was also significantly attenuated by ATRA. Taken together with our previous results where calcium channel blockers reduced cell swelling, the effects of ATRA in attenuating swelling are possibly mediated through its effects in regulating [Ca 2+ ] i . Considering the paucity of agents in attenuating brain edema in ischemia, ATRA has the potential to reduce brain edema and associated neural damage in ischemic injury.
introduction
Vitamin A (VA) is critical for normal cellular growth, differentiation, and death [1, 2] . Within the last 2 decades, a large body of evidence has accumulated which strongly suggests that most of VA's actions in these processes can be explained by the actions of its metabolites, which activate or repress gene transcription through binding Retinoic Acid Receptors (RARs) and/or Retinoid X Receptors (RXR). Alltrans retinoic acid (ATRA), the predominant metabolite of VA, is a natural, high affinity ligand for RARs (K d » 1 nM) whereas it binds very weakly to RXR. RAR and RXR form homo-or heterodimers that bind to specific response elements present in the promoters of target genes thereby initiating transcription [3] . Retinoid receptor proteins are widely distributed in the adult nervous system including the cortex, amygdala, hypothalamus, hippocampus, and striatum indicating a role for such proteins in neural functioning (see [4] for review). Disturbances in retinoic acid signaling have been implicated in Alzheimer's disease [5] , Parkinson's disease [6] , and schizophrenia [7] .
Non-transcriptional mechanisms of ATRA have been reported, including stabilization of mRNA, activation of translation, covalent modification of proteins and direct stimulatory and inhibitory effects of ATRA on enzyme systems [8] . ATRA activates STAT1 rapidly, within 5 min to 2 hr [9] , cAMP/ protein kinase A (PKA)/CREB [10] , Akt/mammalian target of rapamycin (mTOR)/p70 S6 kinase [11] , and protein kinase C (PKC) [12] pathways in various cell types, suggesting that some of its effects on cellular growth, differentiation, and death are independent of transcription.
The protective effect of retinoic acid in response to ischemic injury has been reported in PC12 cells [13] and in cultured hippocampal slices [14] . In addition, the neuroprotective effects of ATRA or its isomers or derivatives have been reported in cerebral ischemic injury in animal studies. 9-cis-retinoic acid, reduced cerebral infarction induced by middle cerebral artery ligation in rats [15, 16] . ATRA also reduced the infarct volume following middle artery occlusion (MCAO) in rats in the cortex [17] and striatum [18] and in mice [19] . However, the effects of ATRA in ischemia on cell swelling, a component of brain edema, are not known.
Brain edema is a key feature of ischemic injury [20] . Brain edema is defined as an abnormal accumulation of fluid in the brain parenchyma resulting in a volumetric enlargement of the cells or tissue. A consequence of this volume increase is the development of increased intracranial pressure leading to brain herniation, irreversible brain damage, and ultimately, death. Brain edema is generally classified into cytotoxic or vasogenic edema [20] . Cytotoxic edema is defined as a cellular swelling with fluid accumulating within the cell in the brain and astrocyte swelling is a major component of cytotoxic edema [21] . Swollen astrocytes following ischemic injury have been reported in cats [22] and rats [23] . Vasogenic edema is characterized by a breakdown of the blood-brain barrier resulting in increased fluid accumulation, originating from blood vessels that amass around cells. Both vasogenic and cytotoxic mechanisms contribute to overall ischemic brain edema [20, 24] . Edema further impairs cerebral perfusion and oxygenation, and contributes to additional ischemic injuries. 
Cell volume determination
Cell volume was estimated by measuring the intracellular water space using the method of Kletzien et al. 1975 [34] , as described by Norenberg et al. 1991 [35] for glial cultures. and MitoTracker CM-H 2 -XROS respectively, as described by Panickar et al. 2002 [36] .
CM-H 2 DCFDA detects ROS/RNS in the cytosolic, nuclear, and mitochondrial compartments whereas MitoTracker CM-H 2 -XROS detects mitochondrial-specific free radicals [37, 38] . Figure 3A and B). This increase was completely blocked by both concentrations of ATRA when compared to OGD (p<0.05; Figure 3A and B).
3.3 ATRA attenuated the depolarization of the mitochondrial inner membrane potential (ΔΨ m ) following OGD Induction of the mPT has been hypothesized to contribute to glial swelling in cultures in traumatic injury [30] and ammonia neurotoxicity [41] . We examined the effects of ATRA on attenuating the OGD-induced decline in (ΔΨ m ). ] i induced cell swelling in lactacidosis-induced glial swelling [43, 44] , and hypo-osmotic swelling in cultured astrocytes [45] . To examine whether ATRA regulates [Ca2+] i , we assessed changes in 
discussion
We demonstrate a protective effect of ATRA on cell swelling in ischemic injury in C6 glial Results from our study support the hypothesis that ATRA exerts such protective effects via a non-transcriptional mechanism.
The well-known effects of ATRA including differentiation and neuronal patterning and neural plasticity generally require a prolonged exposure to ATRA [4] . Given that our cultures were exposed to ATRA from times ranging from neuronal cell line [52] , and the growth cone turning response in mollusc neurons in vitro [53] .
Secondly, blockade of the mPT using the immunosuppressant cylosporin A (with the inability of FK506 to block the mPT) generally suppresses cell swelling in cultures induced by ammonia toxicity [54] , traumatic brain injury [29, 30] , and ischemic injury [28, 33] . Thirdly, ROS/RNS have been hypothesized to induce glial swelling in cultures following ammonia toxicity [41] and TBI [30] . However, we have reported that anti-oxidants including L-NAME, vitamin E, and resveratrol (an antioxidant polyphenol), do not reduce cell swelling following OGD in cultures [33] . In Cytotoxic edema, together with vasogenic edema, can be fatal if unresolved, and may also contribute to secondary damage to cells surviving the primary ischemic insult [67] .
Cytotoxic edema in ischemia is generally an early event when compared to vasogenic edema [20] . Glial swelling also impairs the ability of astrocytes to effectively clear glutamate and K + from the extracellular regions and may further contribute to excitotoxicity [68] (see [69] for review). A reduction in edema may also improve neurological outcome [70] and cerebral microcirculation [71, 72] . Interventions that reduce edema and associated secondary damage may be of considerable importance in diminishing the severity of ischemic injury [73] . 
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